GLP-1 drugs interact with brain addiction pathways and may treat alcohol and substance use disorders | Research

The takeaway

GLP-1 receptor agonists interact with dopaminergic, GABAergic, and opioidergic addiction pathways, showing preclinical and early clinical evidence for reducing alcohol and substance use disorders as a novel treatment application.

Triple pathway engagement
GLP-1 drugs interact with dopamine, GABA, and opioid addiction pathways—providing a biological rationale for treating alcohol and substance use disorders

What the researchers found

GLP-1RAs interact with dopaminergic, GABAergic, and opioidergic addiction pathways. Preclinical + early clinical evidence for reducing alcohol and substance use. Already approved for T2DM, obesity, and OSA—enabling rapid evaluation for ASUDs.

Why it matters

Addiction treatment has extremely limited pharmacotherapy options. GLP-1 drugs represent the most promising new drug class for ASUDs in decades, with a biological rationale spanning multiple addiction pathways.

How the study worked

Narrative review covering ASUD biology, GLP-1RA neurobiological mechanisms in addiction, and emerging clinical evidence.

What this study cannot tell us

Narrative review. Most evidence preclinical. Clinical addiction trials are small and early. Optimal dosing for addiction unknown. Not FDA-approved for this use.

How to read the evidence

Narrative review of preclinical and early clinical evidence. Strong biological rationale needing larger clinical trials.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may be the first medication class to effectively address multiple substance use disorders through shared reward circuit mechanisms. This could transform addiction medicine.

Questions still open

Which GLP-1 drug has the best brain penetration for addiction treatment?
Could GLP-1 drugs replace or complement existing addiction medications?
Will insurance cover GLP-1 drugs prescribed for addiction?

Common questions

Could weight loss drugs treat addiction?

Growing evidence suggests GLP-1 drugs reduce cravings and use of alcohol, nicotine, and other substances by acting on the same brain reward pathways involved in addiction. While not yet approved for this use, the biological rationale is strong and clinical trials are underway.

How do GLP-1 drugs affect addiction pathways?

GLP-1 receptors are found in brain regions controlling reward and pleasure. GLP-1 drugs modulate dopamine (the "pleasure chemical"), GABA (inhibitory signaling), and opioid pathways—all central to addiction. By dampening reward responses, they may reduce the drive to use addictive substances.

Read the original research

GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.

Journal of the Endocrine Society, 9(11), bvaf141

View on PubMed ↗Publisher’s paper ↗

Citation

Srinivasan, Nirupam M; Farokhnia, Mehdi; Farinelli, Lisa A; Ferrulli, Anna; Leggio, Lorenzo. (2025). GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.. Journal of the Endocrine Society, 9(11), bvaf141. https://doi.org/10.1210/jendso/bvaf141